Z
Zentalis Pharmaceuticals
Clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics for cancer treatment. The company operates in the oncology sector, targeting fundamental biological pathways of cancers to create clinically differentiated therapies. Zentalis primarily serves patients suffering from various forms of cancer, including advanced non-Hodgkin lymphoma and acute myeloid leukemia. The company's business model revolves around its Integrated Discovery Engine, which efficiently identifies and develops novel oncology therapies by focusing on clinically validated and commercially proven targets. Zentalis generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. The company aims to improve patient outcomes and make a lasting impact on the field of oncology.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- San Diego, United States
- Listing
- IPO 2020
- Employees
- 121
- Open positions
- 11
- Dealroom signal
- 65.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2023 | $250M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Apr 2022 | $25M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$153M | — |
| 2025 | $0 | -100% | −$153M | — |
| 2024 | $67M | — | −$208M | -308.4% |
| 2023 | $0 | — | −$230M | — |
| 2022 | $0 | — | −$233M | — |
| 2021 | $0 | — | −$269M | — |
| 2020 | $0 | — | −$119M | — |
Growth signals
Latest recorded traffic for Zentalis Pharmaceuticals is 6.5K monthly website visits, down 33.7% over the last three months. Zentalis Pharmaceuticals's team declined 3.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Pharmaron Holding
Mayo Clinic
Viking Global Investors
Alexandria Equities
NuFund Venture Group
Perceptive Advisors
Matrix Capital Management
Highlight Capital- MCMatrix Capital
Series B and later10 investors entered at this stage
Redmile Group
Eventide Asset Management
Surveyor Capital
Tybourne Capital Management
OrbiMed
Lilly Asia Ventures
Logos Capital
Avidity Partners
Farallon Capital Management
Casdin Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zentalis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zentalis Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.